688266 Suzhou Zelgen Biopharmaceuticals
- 56.32
- +3.05+5.73%
Suzhou Zelgen Biopharmaceuticals News
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Investors Are Less Pessimistic Than Expected
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) price-to-sales (or "P/S") ratio of 37x may look like a poor investment opportunity when you consider close to half the companies in the Biotec
Zejing Pharmaceutical (688266): Performance is basically stable in 2023, and multiple products are expected to reach important milestones in 2024
Incident The company released its 2023 annual report, with revenue of 386 million yuan in 2023, up 27.83% year on year; net profit due to mother was -279 million yuan, a year-on-year loss reduction of 39.08%; net profit not attributable to mother -3
Zejing Pharmaceutical (688266): Big products have progressed a lot, many innovative varieties, China and the US double report
Performance: On April 20, 2024, Zejing Pharmaceutical released the 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved revenue of 386 million yuan, +27.83% year-on-year; net profit to mother -2.7
Zejing Pharmaceutical-U (688266): Steady growth in performance, continued promotion of commercialization and innovation pipeline
Core view The company's revenue for the full year of 2023 was 386 million yuan, a year-on-year steady increase of 27.83%. Revenue for the first quarter of 2024 was 108 million yuan, maintaining year-on-year and month-on-month growth. Overall, the company's core products
Zejing Pharmaceutical-U (688266): Revenue continues to grow, and the differentiated pipeline has entered the harvest period
Maintain an “Overweight” rating. In view of changes in the hospital sales environment, the 2024/2025 revenue forecast was adjusted to 766/ 1,454 million yuan (originally 936/1,702 million yuan), and additional 2026 operations were added
Zejing Pharmaceutical (688266): Steady promotion of commercialized core products can be expected
Core view: The company released the 2023 annual report and the 2024 quarterly report: the company achieved revenue of 386 million yuan in 2023, an increase of 27.8% over the previous year; realized net profit to mother - 279 million yuan, a year-on-year decrease of 1.7 million yuan
Zejing Pharmaceutical (688266): The narrowing of losses is optimistic that the volume of new drugs will drive revenue growth
The company achieved revenue of 386 million yuan (+27.83%) in 2023, mainly due to sales volume of donafenib tablets; net loss to mother of 279 million yuan, loss decreased by 179 million yuan year on year; Q1-Q in 2023
Zejing Pharmaceutical (688266): Commercialization is progressing steadily, looking forward to the listing of Jacketinib
Event: The company released its 2023 annual report and achieved operating revenue of 390 million yuan (+27.8%) during the reporting period. The commercialization of donafenib is progressing steadily, and coverage continues to expand. The commercialization of donafenib progresses steadily, and it will be put into operation in 2023
SDIC Securities released a research report on April 22 stating that it maintains the purchase rating of Zejing Pharmaceuticals (688266.SH), and the target price is 64.20 yuan. The main reasons for the rating include: 1) A number of innovative drugs are gr
SDIC Securities released a research report on April 22 stating that it maintains the purchase rating of Zejing Pharmaceuticals (688266.SH), and the target price is 64.20 yuan. The main reasons for the rating include: 1) A number of innovative drugs are gradually entering the commercialization stage; 2) Early innovative drug pipelines have large reserves, and the potential for subsequent product pipelines is high. (Mainichi Keizai Shimbun)
Huaan Securities released a research report on April 21 stating that it gave Zejing Pharmaceutical (688266.SH) a purchase rating. The main reasons for the rating include: 1) steady increase in operational efficiency and positive operating cash flow for th
Huaan Securities released a research report on April 21 stating that it gave Zejing Pharmaceutical (688266.SH) a purchase rating. The main reasons for the rating include: 1) steady increase in operational efficiency and positive operating cash flow for the first time; 2) existing commercial products have resumed growth, and 24H1 commercialization highlights are concentrated; 3) the subsequent arrangement of BIC and FIC pipelines, and the dual anti-triple antibody platform has entered the verification period. (Mainichi Keizai Shimbun)
Zejing Pharmaceutical (688266): 23FY and 24Q1 stable and stable innovative multi-antibody platforms have been verified one after another
Incident: On April 20, 2024, Zejing Pharmaceutical released its 2023 annual report. During the reporting period, the company achieved operating income of 386 million yuan, +27.83% year-on-year; net profit to mother - 279 million yuan, +3 year on year
Zejing Pharmaceutical (688266): A number of innovative drugs are gradually entering the commercialization phase, and subsequent product pipelines have high potential
Event: The company publishes the 2023 Annual Report and the First Quarter 2024 Report. In 2023, the company achieved operating income of 386 million yuan, an increase of 27.83% over the previous year; realized net profit to mother - 279 million yuan
Zejing Pharmaceutical (688266): Optimistic about new product drive & innovation catalysis
Investment highlights In 2023, the company's revenue grew relatively rapidly, and profit-side losses narrowed. The company's pipeline has accelerated. Donafinil continues to be released, recombinant human thrombin has been approved, commercialization of jacketinib and rhTSH is imminent, and the core products are located
Zejing Pharmaceutical (688266.SH): net loss of 279 million yuan in 2023
Gelonghui, April 19丨Zejing Pharmaceutical (688266.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 386 million yuan, an increase of 27.83% over the previous year; net profit attributable to shareholders of listed companies - 279 million yuan; basic earnings per share - 1.09 yuan.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Market Cap Dropped CN¥1.2b Last Week; Retail Investors Bore the Brunt
Key Insights Suzhou Zelgen BiopharmaceuticalsLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 13 investor
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials
Suzhou Zejing Biopharmaceutical (SHA:688266) said the National Medical Products Administration (NMPA) issued a Clinical Trial Approval for its Jacktinib Cream to treat non-segmental vitiligo, accordin
Express News | Zejing Pharmaceutical: Jacketinib Hydrochloride Cream Receives Drug Clinical Trial Approval Notice
Is Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe
Zejing Pharmaceutical (688266): Steady growth in performance, commercialization of core products can be expected
Core view: The company released the 2023 annual performance report: the company achieved revenue of 386 million yuan in 2023, an increase of 27.83% over the previous year; realized net profit to mother - 279 million yuan, a year-on-year loss reduction of about 179 million yuan
Zejing Pharmaceutical (688266): Innovative leading potential is beginning to show, and differentiated pipelines are blossoming
Introduction to this report: Based on differentiated research and development, Zejing Pharmaceutical is newly marketed with recombinant human thrombin. Jacketinib is about to be approved, and the innovation pipeline is entering the harvest period one after another. Covered for the first time, an increase in holdings rating is given. Key investment points: First coverage, rating for increasing holdings.
Analysis
Price Target
No Data
